Tiếng ViệtOn July 5, 2017, the 12th Annual Conference of China’s Top 100 Pharmaceutical Companies was grandly held at Yun’an Huidu Hotel, Kunming, as part of National Pharmaceutical Week 2017. This prestigious ranking is organized by a committee comprising Southern Pharmaceutical Economic Research Institute, renowned universities, research institutes, pharmaceutical industry associations, and financial media outlets. Since its launch in 2006, this ranking has become one of China’s most authoritative and influential in the pharmaceutical sector.
🏆 Yabang Pharmaceuticals, a subsidiary of Jiangsu Yabang Group, climbed from rank 66 to 63 in this year’s list, reflecting its continuous growth and commitment to excellence in the industry.
Wanfeile® Recognized as a Leading Pharmaceutical Retail Product
💊 Yabang’s flagship brand Wanfeile® was included in the “New Products in China’s Pharmaceutical Retail Market” List for the second consecutive year. Its recognition is based on a comprehensive evaluation of:
✔️ Product Safety & Efficacy
✔️ Market Reach
✔️ Annual Sales Performance
✔️ Brand Recognition
✔️ Recommendation Rate by Retail Staff
✔️ Price Competitiveness
This recognition reaffirms Wanfeile®’s market value and growth potential, further strengthening Yabang’s position in China’s pharmaceutical industry.
Opportunities & Challenges in the Pharmaceutical Industry
The “13th Five-Year Plan” has introduced key regulatory policies, such as:
🔹 Consistency Evaluation of Generic Drugs
🔹 Medical Insurance Cost Control
🔹 National Drug Price Negotiations
These policies pose both challenges and opportunities for pharmaceutical enterprises. Yabang Pharmaceuticals is determined to seize these opportunities, leveraging its strong development momentum to overcome future obstacles.
📈 2016’s achievements reflect our dedication and resilience. In 2017, Yabang Pharmaceuticals will continue striving for excellence, ensuring another year of success!
